The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Stocks erase losses after Spanish auction

Tue, 28th Aug 2012 11:47

- Spanish bond auction lifts sentiment- Miners lower on concerns over Japan- Chemring drops profit warning.London's blue-chip index was trading broadly flat by midday, having erased all of the morning's losses, after a solid Spanish bond auction eased concerns about the heavily indebted Eurozone country.Miners were providing a drag on the FTSE 100 this morning on concerns about Japan, the world's third-largest economy. The Japanese government has reduced its view on personal consumption, housing construction, exports, imports and industrial output for the first 10 months of the year. "The Japanese economy is on the way to recovery at a moderate pace, partly due to reconstruction demand, while some weak movements are seen recently," the Cabinet Office said in its monthly report. JPMorgan Securities Japan and BNP Paribas are forecasting a 0.3% and 0.9% decline in third-quarter Japanese gross domestic product (GDP), respectively.Turning to Spain, the Treasury raised €3.607bn in short-term debt this morning, above the top-end of its target rage of €2.5-3.5bn. Borrowing costs dropped dramatically and demand increased significantly compared with the previous auction in July. According to the country's national statistics institute, Spanish GDP declined at a 1.3% annual rate in the second quarter, compared with the initial estimate of a 1% contraction. Markets continue to wait official news from the European Central Bank (ECB) regarding its proposed bond-buying programme. However, analyst Craig Erlam from Alpari said that recent market chatter has shown some consistency: "There have been numerous reports recently that claim to have inside knowledge on the matter. While they all differ slightly, there is also a lot of consistency. Based on these reports, it looks likely that the ECB will target short term debt yields, which will include a non-fixed yield cap on Spanish and Italian bonds," he said.However, ECB member Jörg Asmussen has said over the weekend that the EFSF bailout fund must take the lead in the purchase of any sovereign debt before the ECB steps in. "The ECB council will continue to decide in full independence whether, when and how it will purchase bonds on the secondary market," he said.FTSE 100: Kingfisher, G4S and miners weigh on benchmark indexB&Q owner Kingfisher was the heaviest faller of the day after Bank of America Merrill Lunch downgraded its rating on the stock to 'underperform'. Security giant G4S fell after expressing disappointment over the problems related to its Olympics contract, saying that it will incur a £50m loss on the contract in the first half. Meanwhile, the company said that a restructuring of its overhead structure will lead the loss of 1,100 jobs. Nevertheless, the firm revealed that turnover at constant exchange rates rose 7.5% while profits were flat. Miners were firmly out of favour this morning on concerns over the Japanese economy. BHP Billiton fell after announcing the sale of its Yeelirrie uranium deposit in Western Australia to Cameco for $430m. BHP and sector peers ENRC, Kazakhmys and Vedanta were also lower after Morgan Stanley reduced its target price for all four stocks. Drugs giant AstraZeneca was lower after saying that it has appointed Roche's Chief Operating Officer as its new Chief Executive Officer. Meanwhile, the firm also announced that the European Commission has granted marketing authorisation to its ZINFORO treatment. Sector peer GlaxoSmithKline was suffering from a downgrade by UBS.Bunzl, the international distribution and outsourcing group, fell despite saying that pre-tax profits and revenues in the first half rose 9% and 7%, respectively. FTSE 250: Chemring drops after profit warningDefence contractor Chemring dropped after it issued a profits warning, saying a computer glitch and production delays are likely to wipe £15m off full-year earnings as it considers a takeover offer from private equity giant Carlyle.Heading the other way was chemicals group Yule Catto after reporting a pre-tax profit of £56m in the first half, up from £52.4m the year before. Sales, however, fell to £603.3m from £664.3m.FTSE 100 - RisersITV (ITV) 85.00p +1.74%Carnival (CCL) 2,128.00p +1.72%Barclays (BARC) 190.20p +1.60%CRH (CRH) 1,149.00p +1.59%Fresnillo (FRES) 1,606.00p +1.52%Capital Shopping Centres Group (CSCG) 332.90p +1.22%United Utilities Group (UU.) 719.50p +1.20%BT Group (BT.A) 217.50p +1.07%Sainsbury (J) (SBRY) 332.60p +0.94%Glencore International (GLEN) 370.00p +0.86%FTSE 100 - FallersKingfisher (KGF) 275.60p -3.54%Evraz (EVR) 239.70p -2.88%Kazakhmys (KAZ) 642.00p -2.80%G4S (GFS) 259.10p -2.67%Eurasian Natural Resources Corp. (ENRC) 330.50p -2.48%Bunzl (BNZL) 1,084.00p -2.43%Vedanta Resources (VED) 906.00p -2.00%Marks & Spencer Group (MKS) 364.30p -1.99%IMI (IMI) 840.50p -1.93%InterContinental Hotels Group (IHG) 1,587.00p -1.79%FTSE 250 - RisersYule Catto & Co (YULC) 152.80p +7.76%Moneysupermarket.com Group (MONY) 138.10p +5.42%Ted Baker (TED) 1,000.00p +3.41%Renishaw (RSW) 1,568.00p +2.55%Dialight (DIA) 1,099.00p +2.33%Imagination Technologies Group (IMG) 578.50p +2.12%Home Retail Group (HOME) 95.15p +2.04%Homeserve (HSV) 216.30p +1.93%St. Modwen Properties (SMP) 202.40p +1.71%COLT Group SA (COLT) 119.20p +1.71%FTSE 250 - FallersChemring Group (CHG) 324.00p -12.55%Bumi (BUMI) 335.30p -5.55%Heritage Oil (HOIL) 191.00p -4.45%Cairn Energy (CNE) 285.10p -3.78%BTG (BTG) 310.30p -2.64%Afren (AFR) 126.80p -2.39%Cape (CIU) 188.50p -2.38%Bwin.party Digital Entertainment (BPTY) 92.90p -2.26%Perform Group (PER) 372.00p -2.11%NMC Health (NMC) 193.00p -2.03%BC
More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.